---
schema_version: "secwatch.filing_event.v1"
accession: "0001689548-22-000099"
form_type: "8-K"
ticker: "PRAX"
cik: "0001689548"
company_name: "Praxis Precision Medicines, Inc."
filed_at: "2022-07-26T23:59:59+00:00"
generated_at: "2026-06-24T08:47:37.491148+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Praxis CMO Bernard Ravina to step down, become part-time strategic advisor

## Summary
- Bernard Ravina, Chief Medical Officer, transitions to part-time strategic advisor effective Aug 1, 2022.
- Cash payment of $373,688 paid over consulting period ending May 1, 2023.
- Outstanding equity awards will continue to vest during consulting period subject to service.
- Health benefits continuation provided during consulting period; payment subject to signing release.
- Ravina resigns from all officer and director positions with the Company.

## SEC filing metadata
- accession: 0001689548-22-000099
- form_type: 8-K
- ticker: PRAX
- cik: 0001689548
- company_name: Praxis Precision Medicines, Inc.
- filed_at: 2022-07-26T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689548/000168954822000099/0001689548-22-000099-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689548/000168954822000099/prax-20220721.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689548-22-000099
- JSON: https://secwatch.observer/filing/0001689548-22-000099.json
- Plain text: https://secwatch.observer/filing/0001689548-22-000099.txt

## Key facts
- Executive change
  Bernard Ravina changed role as Chief Medical Officer at Praxis Precision Medicines, Inc..
  - Action: transitioned
  - Role: Chief Medical Officer
  source text: On July 21, 2022, Bernard Ravina, Chief Medical Officer of Praxis Precision Medicines, Inc. (the “ Company ”), who is currently on leave attending to family medical matters, and the Company mutually decided that Dr. Ravina will transition from his full-time position as Chief Medical Officer to a part-time role as strategic advisor to the Company on August 1, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1689548/000168954822000099/0001689548-22-000099-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.